Global Blood Therapeutics Stock Price, News & Analysis (NASDAQ:GBT)

$61.50 -4.40 (-6.68 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$61.50
Today's Range$61.40 - $68.05
52-Week Range$23.55 - $68.05
Volume867,586 shs
Average Volume1.14 million shs
Market Capitalization$2.90 billion
P/E Ratio-24.12
Dividend YieldN/A
Beta4.78

About Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics logoGlobal Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700

Debt

Debt-to-Equity RatioN/A
Current Ratio14.05%
Quick Ratio14.05%

Price-To-Earnings

Trailing P/E Ratio-24.1175524801864
Forward P/E Ratio-24.02
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.99 per share
Price / Book12.32

Profitability

Trailing EPS($2.55)
Net Income$-82,460,000.00
Net MarginsN/A
Return on Equity-40.04%
Return on Assets-37.24%

Miscellaneous

Employees95
Outstanding Shares46,010,000

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics Inc (NASDAQ:GBT) released its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.04. During the same period in the previous year, the business earned ($0.58) EPS. View Global Blood Therapeutics' Earnings History.

When will Global Blood Therapeutics make its next earnings announcement?

Global Blood Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Global Blood Therapeutics.

Where is Global Blood Therapeutics' stock going? Where will Global Blood Therapeutics' stock price be in 2018?

14 brokerages have issued 12-month target prices for Global Blood Therapeutics' stock. Their predictions range from $46.00 to $91.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $67.93 in the next year. View Analyst Ratings for Global Blood Therapeutics.

What are Wall Street analysts saying about Global Blood Therapeutics stock?

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "At ASH, Global Blood announced multi-dose Phase 2a data with voxelotor (GBT440), in adolescent (ages 12-17) patients." (12/11/2017)
  • 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (12/6/2017)
  • 3. Cowen Inc analysts commented, "GBT reported Q3 earnings last week and provided a brief summary of their progress." (11/9/2017)
  • 4. Wedbush analysts commented, "Global Blood Therapeutics (GBT) is developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease (SCD) and to improve blood oxygenation characteristics and quality of life for IPF. In 2017, we see release of Phase 2a GBT440 testing in IPF as the most material catalyst unless GBT is acquired. We calculate that the recent uptick following acquisition speculation is too low."We believe GBT440's emerging clinical profile suggests potential for disease modification and becoming the foundation treatment for SCD. To date the emerging clinical profile includes a convenient once daily oral dosing; being safe and well tolerated and recent longer-term dosing suggests durability of effect and in our view partially de-risks Phase 3. Investor concerns include lack of dose response, new PRO and competition." (3/20/2017)
  • 5. JPMorgan Chase & Co. analysts commented, "This evening GBT released 4Q results via press release (no conference call, as usual). The update was largely review and in-line with recent commentary; see our takeaways from the J.P. Morgan Healthcare Conference here. More significant than tonight’s print was Reuter’s report last week (here) that Novo Nordisk may have interest in GBT, and a subsequent Reuter’s story (here) that quoted NVO’s CEO saying “In my view we should do smaller deals; low single-digit billions of dollars.” On this front, we do believe that GBT could be a strong strategic fit for companies currently involved in the non-oncology hematology space. More broadly, we continue to think GBT440 is a promising wholly owned asset targeting a large and underserved market with the potential for initial IPF data later this year and a key sickle cell update currently anticipated in 2018." (3/15/2017)

Who are some of Global Blood Therapeutics' key competitors?

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:

  • Ted W. Love M.D., President, Chief Executive Officer, Director
  • Jeffrey S. Farrow, Chief Financial Officer
  • Peter Radovich, Senior Vice President, Operations
  • Hing L. Sham, Senior Vice President, Research
  • Jung E. Choi, Chief Business and Strategy Officer
  • Tricia Borga Suvari Esq., Chief Legal Officer
  • Charles J. Homcy M.D., Director
  • Wendy L. Yarno, Director
  • Willie L. Brown Jr, Independent Director
  • Scott W. Morrison, Independent Director

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Who owns Global Blood Therapeutics stock?

Global Blood Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (10.63%), BlackRock Inc. (7.22%), Citadel Advisors LLC (1.56%), RTW Investments LP (1.31%), Millennium Management LLC (1.04%) and Sectoral Asset Management Inc (0.96%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Jung Choi, Kevin P Starr, Perceptive Advisors Llc, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.

Who sold Global Blood Therapeutics stock? Who is selling Global Blood Therapeutics stock?

Global Blood Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, BlackRock Inc., Artal Group S.A., Sectoral Asset Management Inc, Compagnie Lombard Odier SCmA, Fernwood Investment Management LLC, Guggenheim Capital LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Charles J Homcy, Deval L Patrick, Jung Choi, Peter Radovich and Robert I Tepper. View Insider Buying and Selling for Global Blood Therapeutics.

Who bought Global Blood Therapeutics stock? Who is buying Global Blood Therapeutics stock?

Global Blood Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, RTW Investments LP, Millennium Management LLC, Citadel Advisors LLC, Farallon Capital Management LLC, ING Groep NV, Monashee Investment Management LLC and Driehaus Capital Management LLC. View Insider Buying and Selling for Global Blood Therapeutics.

How do I buy Global Blood Therapeutics stock?

Shares of Global Blood Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of Global Blood Therapeutics stock can currently be purchased for approximately $61.50.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $2.90 billion. The company earns $-82,460,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Global Blood Therapeutics employs 95 workers across the globe.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]


MarketBeat Community Rating for Global Blood Therapeutics (GBT)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  364
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Global Blood Therapeutics (NASDAQ:GBT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $67.93$64.08$56.73$52.91
Price Target Upside: 12.56% upside15.56% upside47.54% upside80.56% upside

Global Blood Therapeutics (NASDAQ:GBT) Consensus Price Target History

Price Target History for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ:GBT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018Janney Montgomery ScottInitiated CoverageBuy -> Buy$75.00MediumView Rating Details
1/23/2018William BlairInitiated CoverageOutperform -> Outperform$80.00HighView Rating Details
1/11/2018HC WainwrightSet Price TargetBuy$73.00MediumView Rating Details
12/15/2017WedbushReiterated RatingOutperform$73.00LowView Rating Details
12/14/2017Needham & Company LLCBoost Price TargetBuy -> Buy$51.00 -> $70.00LowView Rating Details
12/12/2017OppenheimerSet Price TargetBuy$53.00 -> $79.00HighView Rating Details
12/11/2017NomuraBoost Price TargetBuy$91.00HighView Rating Details
12/11/2017Cantor FitzgeraldSet Price TargetBuy$61.00HighView Rating Details
11/9/2017CowenReiterated RatingBuy$83.00N/AView Rating Details
11/6/2017SunTrust BanksBoost Price TargetBuy$67.00N/AView Rating Details
10/23/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$51.00 -> $56.00N/AView Rating Details
3/20/2017Roth CapitalSet Price TargetBuy$47.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$50.00N/AView Rating Details
9/30/2016Wells Fargo & CoInitiated CoverageOutperform$75.00 -> $23.05N/AView Rating Details
2/22/2016Goldman Sachs GroupLower Price Target$43.00 -> $26.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Global Blood Therapeutics (NASDAQ:GBT) Earnings History and Estimates Chart

Earnings by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ GBT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.72)N/AView Earnings Details
11/2/2017Q3 2017($0.62)($0.66)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.61)($0.55)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.71)($0.60)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.64)($0.74)ViewN/AView Earnings Details
11/9/2016Q316($0.58)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.63)($0.58)ViewN/AView Earnings Details
5/12/2016Q1($0.48)($0.56)ViewN/AView Earnings Details
3/29/2016Q4($0.64)($0.53)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.71)($0.90)ViewN/AView Earnings Details
9/24/2015Q2 2015($4.04)($4.84)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Global Blood Therapeutics (NASDAQ:GBT) Earnings Estimates

2018 EPS Consensus Estimate: ($2.77)
2019 EPS Consensus Estimate: ($3.23)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.66)($0.66)($0.66)
Q2 20181($0.69)($0.69)($0.69)
Q3 20181($0.70)($0.70)($0.70)
Q4 20181($0.72)($0.72)($0.72)
Q1 20191($0.75)($0.75)($0.75)
Q2 20191($0.79)($0.79)($0.79)
Q3 20191($0.82)($0.82)($0.82)
Q4 20191($0.87)($0.87)($0.87)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Global Blood Therapeutics (NASDAQ:GBT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Global Blood Therapeutics (NASDAQ GBT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 87.81%
Insider Trades by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ GBT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Jung ChoiInsiderSell3,000$62.95$188,850.00140,877View SEC Filing  
2/1/2018Peter RadovichInsiderSell812$57.30$46,527.606,221View SEC Filing  
1/23/2018Peter RadovichInsiderSell30,000$60.00$1,800,000.0033,581View SEC Filing  
1/17/2018Jung ChoiInsiderSell3,000$52.85$158,550.00137,255View SEC Filing  
1/10/2018Peter RadovichInsiderSell15,000$50.00$750,000.0017,684View SEC Filing  
12/19/2017Perceptive Advisors LlcMajor ShareholderBuy175,000$38.00$6,650,000.00View SEC Filing  
12/18/2017Jung ChoiInsiderSell3,000$36.55$109,650.00135,255View SEC Filing  
10/30/2017Peter RadovichVPSell12,500$35.00$437,500.002,684View SEC Filing  
10/27/2017Charles J HomcyDirectorSell70,000$33.97$2,377,900.0083,328View SEC Filing  
10/17/2017Jung ChoiInsiderSell3,000$32.65$97,950.00138,455View SEC Filing  
9/29/2017Jung ChoiInsiderSell3,000$30.00$90,000.00140,055View SEC Filing  
8/31/2017Jung ChoiInsiderSell3,000$30.00$90,000.00141,655View SEC Filing  
7/25/2017Deval L PatrickDirectorSell27,053$29.69$803,203.5712,053View SEC Filing  
7/21/2017Jung ChoiInsiderSell3,000$30.00$90,000.00143,255View SEC Filing  
4/6/2017Robert I TepperMajor ShareholderSell31,225$33.23$1,037,606.75229,773View SEC Filing  
12/16/2016Kevin P StarrMajor ShareholderSell108,955$16.00$1,743,280.0082,544View SEC Filing  
1/7/2016John SchembriinsiderBuy1,500$21.57$32,355.001,500View SEC Filing  
12/22/2015Eleanor RamosinsiderBuy11,000$20.93$230,230.0011,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Global Blood Therapeutics (NASDAQ GBT) News Headlines

Source:
DateHeadline
Global Blood Therapeutics Inc (GBT) Insider Sells $188,850.00 in StockGlobal Blood Therapeutics Inc (GBT) Insider Sells $188,850.00 in Stock
www.americanbankingnews.com - February 21 at 9:24 PM
Global Blood Therapeutics Inc to Post FY2022 Earnings of ($0.65) Per Share, SunTrust Banks Forecasts (GBT)Global Blood Therapeutics Inc to Post FY2022 Earnings of ($0.65) Per Share, SunTrust Banks Forecasts (GBT)
www.americanbankingnews.com - February 19 at 9:18 AM
Global Blood Therapeutics (GBT) Rating Increased to Strong-Buy at BidaskClubGlobal Blood Therapeutics (GBT) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - February 17 at 12:26 PM
With an Eye on Biotech, Heres Todays Trading ThesisWith an Eye on Biotech, Here's Today's Trading Thesis
finance.yahoo.com - February 15 at 5:06 PM
Global Blood Therapeutics (GBT) Research Coverage Started at Janney Montgomery ScottGlobal Blood Therapeutics (GBT) Research Coverage Started at Janney Montgomery Scott
www.americanbankingnews.com - February 13 at 8:08 PM
GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference - GlobeNewswire (press release)GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 8 at 6:45 AM
GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare ConferenceGBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 6:45 AM
The Confidence in the Dip Buyers Has WeakenedThe Confidence in the Dip Buyers Has Weakened
finance.yahoo.com - February 8 at 6:45 AM
Global Blood Therapeutics Inc (GBT) Given Average Recommendation of "Buy" by BrokeragesGlobal Blood Therapeutics Inc (GBT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 6 at 5:26 PM
Heres Why Global Blood Therapeutics Inc. Soared 47.1% in JanuaryHere's Why Global Blood Therapeutics Inc. Soared 47.1% in January
www.fool.com - February 5 at 1:07 PM
Global Blood Therapeutics Inc (GBT) Insider Sells $46,527.60 in StockGlobal Blood Therapeutics Inc (GBT) Insider Sells $46,527.60 in Stock
www.americanbankingnews.com - February 2 at 10:02 PM
Insider Selling: Global Blood Therapeutics Inc (GBT) Insider Sells 30,000 Shares of StockInsider Selling: Global Blood Therapeutics Inc (GBT) Insider Sells 30,000 Shares of Stock
www.americanbankingnews.com - January 25 at 9:12 PM
First Week of September 21st Options Trading For Global Blood Therapeutics (GBT) - NasdaqFirst Week of September 21st Options Trading For Global Blood Therapeutics (GBT) - Nasdaq
www.nasdaq.com - January 25 at 3:27 PM
Global Blood Therapeutics Inc Forecasted to Earn FY2017 Earnings of ($2.49) Per Share (GBT)Global Blood Therapeutics Inc Forecasted to Earn FY2017 Earnings of ($2.49) Per Share (GBT)
www.americanbankingnews.com - January 25 at 7:50 AM
William Blair Starts Global Blood Therapeutics (GBT) at Outperform; Says 30-50% Upside Remains, Including Potential ... - StreetInsider.comWilliam Blair Starts Global Blood Therapeutics (GBT) at Outperform; Says 30-50% Upside Remains, Including Potential ... - StreetInsider.com
www.streetinsider.com - January 24 at 3:30 PM
William Blair Values Global Blood Therapeutics Stock At $80 - BenzingaWilliam Blair Values Global Blood Therapeutics' Stock At $80 - Benzinga
www.benzinga.com - January 23 at 3:31 PM
William Blair Values Global Blood Therapeutics Stock At $80William Blair Values Global Blood Therapeutics' Stock At $80
finance.yahoo.com - January 23 at 3:31 PM
Global Blood Therapeutics Inc (GBT) Insider Sells $158,550.00 in StockGlobal Blood Therapeutics Inc (GBT) Insider Sells $158,550.00 in Stock
www.americanbankingnews.com - January 18 at 9:58 PM
FY2017 Earnings Forecast for Global Blood Therapeutics Inc (GBT) Issued By OppenheimerFY2017 Earnings Forecast for Global Blood Therapeutics Inc (GBT) Issued By Oppenheimer
www.americanbankingnews.com - January 15 at 2:38 AM
Global Blood Therapeutics Inc Expected to Earn FY2022 Earnings of $4.30 Per Share (GBT)Global Blood Therapeutics Inc Expected to Earn FY2022 Earnings of $4.30 Per Share (GBT)
www.americanbankingnews.com - January 13 at 3:12 PM
Global Blood Therapeutics Inc (GBT) Receives Average Rating of "Buy" from BrokeragesGlobal Blood Therapeutics Inc (GBT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 12 at 6:32 PM
Peter Radovich Sells 15,000 Shares of Global Blood Therapeutics Inc (GBT) StockPeter Radovich Sells 15,000 Shares of Global Blood Therapeutics Inc (GBT) Stock
www.americanbankingnews.com - January 12 at 12:36 AM
Reviewing CytRx (CYTR) and Global Blood Therapeutics (GBT)Reviewing CytRx (CYTR) and Global Blood Therapeutics (GBT)
www.americanbankingnews.com - January 11 at 8:14 AM
Global Blood Therapeutics (GBT) Announces FDA Breakthrough Therapy Designation for Voxelotor for Treatment of SCDGlobal Blood Therapeutics (GBT) Announces FDA Breakthrough Therapy Designation for Voxelotor for Treatment of SCD
www.streetinsider.com - January 10 at 9:51 AM
Why Global Blood Therapeutics Inc Is Rising TodayWhy Global Blood Therapeutics Inc Is Rising Today
www.fool.com - January 9 at 2:56 PM
BRIEF-GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell DiseaseBRIEF-GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease
www.reuters.com - January 9 at 9:43 AM
GBT to Present at the 36th Annual J.P. Morgan Healthcare ConferenceGBT to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 5:10 PM
Head-To-Head Analysis: Global Blood Therapeutics (GBT) versus Spectrum Pharmaceuticals (SPPI)Head-To-Head Analysis: Global Blood Therapeutics (GBT) versus Spectrum Pharmaceuticals (SPPI)
www.americanbankingnews.com - January 3 at 8:12 AM
Global Blood Therapeutics: The Significance Of ASH Updates - Seeking AlphaGlobal Blood Therapeutics: The Significance Of ASH Updates - Seeking Alpha
seekingalpha.com - December 28 at 6:37 AM
Global Blood Therapeutics (GBT) Downgraded by BidaskClubGlobal Blood Therapeutics (GBT) Downgraded by BidaskClub
www.americanbankingnews.com - December 24 at 8:15 AM
Upcoming Conversation With An Expert: Whats The Potential Of Global Blood Therapeutics Voxelotor (GBT440) In ... - Seeking AlphaUpcoming Conversation With An Expert: What's The Potential Of Global Blood Therapeutics' Voxelotor (GBT440) In ... - Seeking Alpha
seekingalpha.com - December 22 at 9:54 AM
GBT Appoints Wendy L. Yarno to Board of Directors - GlobeNewswire (press release)GBT Appoints Wendy L. Yarno to Board of Directors - GlobeNewswire (press release)
globenewswire.com - December 22 at 9:54 AM
GBT Appoints Wendy L. Yarno to Board of DirectorsGBT Appoints Wendy L. Yarno to Board of Directors
finance.yahoo.com - December 22 at 9:54 AM
Insider Selling: Global Blood Therapeutics Inc (GBT) Insider Sells 3,000 Shares of StockInsider Selling: Global Blood Therapeutics Inc (GBT) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - December 20 at 6:04 PM
Perceptive Advisors Llc Purchases 175,000 Shares of Global Blood Therapeutics Inc (GBT) StockPerceptive Advisors Llc Purchases 175,000 Shares of Global Blood Therapeutics Inc (GBT) Stock
www.americanbankingnews.com - December 19 at 11:32 PM
Global Blood Therapeutics Inc (GBT) Receives Average Recommendation of "Buy" from AnalystsGlobal Blood Therapeutics Inc (GBT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 18 at 8:30 PM
Notable Mover Report On Dec 14, 2017 - Global Blood Therapeutics - Seeking AlphaNotable Mover Report On Dec 14, 2017 - Global Blood Therapeutics - Seeking Alpha
seekingalpha.com - December 16 at 5:03 PM
Global Blood Therapeutics (GBT) Stock Rating Reaffirmed by WedbushGlobal Blood Therapeutics (GBT) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - December 15 at 8:38 PM
5 Stocks To Watch For December 15, 2017 - Benzinga5 Stocks To Watch For December 15, 2017 - Benzinga
www.benzinga.com - December 15 at 10:12 AM
Global Blood Therapeutics (GBT) Says it Priced $100M Common Stock Offering - StreetInsider.comGlobal Blood Therapeutics (GBT) Says it Priced $100M Common Stock Offering - StreetInsider.com
www.streetinsider.com - December 15 at 10:12 AM
Global Blood Therapeutics Prices a $100.0 Million Common Stock Public OfferingGlobal Blood Therapeutics Prices a $100.0 Million Common Stock Public Offering
finance.yahoo.com - December 15 at 10:12 AM
Stock Traders Purchase High Volume of Put Options on Global Blood Therapeutics (GBT)Stock Traders Purchase High Volume of Put Options on Global Blood Therapeutics (GBT)
www.americanbankingnews.com - December 15 at 3:38 AM
FY2020 EPS Estimates for Global Blood Therapeutics Inc Boosted by Analyst (GBT)FY2020 EPS Estimates for Global Blood Therapeutics Inc Boosted by Analyst (GBT)
www.americanbankingnews.com - December 14 at 10:16 PM
7 Stocks Moving In Thursdays After-Hours Session - Benzinga7 Stocks Moving In Thursday's After-Hours Session - Benzinga
www.benzinga.com - December 14 at 5:40 PM
Global Blood Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)Global Blood Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - December 14 at 5:40 PM
Global Blood Therapeutics (GBT) Price Target Increased to $70.00 by Analysts at Needham & Company LLCGlobal Blood Therapeutics (GBT) Price Target Increased to $70.00 by Analysts at Needham & Company LLC
www.americanbankingnews.com - December 14 at 10:22 AM
Global Blood Therapeutics (GBT) Stock Rating Upgraded by BidaskClubGlobal Blood Therapeutics (GBT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 12 at 10:48 PM
Is Global Blood Therapeutics Inc’s (undefined:GBT) CEO Overpaid Relative To Its Peers?Is Global Blood Therapeutics Inc’s (undefined:GBT) CEO Overpaid Relative To Its Peers?
finance.yahoo.com - December 12 at 5:32 PM
Global Blood Therapeutics And Crispr - Which Firm Will Capture The Lucrative Hemoglobinopathy Market? - Seeking AlphaGlobal Blood Therapeutics And Crispr - Which Firm Will Capture The Lucrative Hemoglobinopathy Market? - Seeking Alpha
seekingalpha.com - December 12 at 10:10 AM
Oppenheimer Reiterates "$79.00" Price Target for Global Blood Therapeutics (GBT)Oppenheimer Reiterates "$79.00" Price Target for Global Blood Therapeutics (GBT)
www.americanbankingnews.com - December 12 at 10:04 AM

SEC Filings

Global Blood Therapeutics (NASDAQ:GBT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Global Blood Therapeutics (NASDAQ:GBT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Global Blood Therapeutics (NASDAQ GBT) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.